P eriodontal disease is a local chronic inflammatory reaction that affects and destroys supporting tissues of the teeth, leading to gingival bleeding, resorption of alveolar bone, and clinical attachment loss (AL) of teeth. 1 Previous studies have shown that periodontitis may have profound effects on systemic health. 2 Several studies have indicated that periodontitis is associated with diabetes and obesity, [3] [4] [5] and individuals with obesity or metabolic syndrome have an increased risk of developing periodontitis. 6, 7 Nevertheless, little is known about the biologic mechanism between glycometabolism and periodontitis.
Adipose tissue participates in energy homeostasis regulation and is also an endocrine organ that secretes active substances such as adipokines. Adipokines are hormone-like proteins, including leptin, visfatin, proinflammatory cytokines, and plasminogen activator inhibitor 1. 8 These hormone-like proteins play an important role in the immune system, 9 and some of these cytokines appear to be key regulators of the inflammatory response. Importantly, some of them are involved in the progression of periodontitis.
Visfatin, also known as pre-B cell colony-enhancing factor, is a highly conserved protein among different species. 10 Visfatin is also significantly homologous in sequence and function with nicotinamide phosphoribosyltransferase, which is a crucial enzyme associated with nicotinamide adeninedinucleotide biosynthesis. 11 The coenzyme nicotinamide adeninedinucleotide participates in the cellular respiration processes of all living cells and may play a role in the development of type 2 diabetes mellitus (T2DM). 12 Periodontal inflammation can upregulate proinflammatory cytokines such as interleukin (IL)-6 and IL-1b, which in turn can lead to a high expression of visfatin in periodontal tissues. Visfatin may contribute to periodontitis through upregulation of matrix metalloproteinase 1 and chemokine CC-motif ligand 2 in periodontal ligament cells. 13 Pradeep et al. 14 found increased visfatin levels in serum and gingival crevicular fluid (GCF) of patients with chronic periodontitis (CP) compared with periodontal healthy individuals, and the concentration of visfatin in GCF and serum was found to be high in CP and decreased after non-surgical periodontal treatment. 15 However, serum and GCF visfatin concentrations in patients with T2DM and CP before and after non-surgical periodontal treatment have not been explored. Hence, the aim of the present study is to assess the concentrations of visfatin in serum and GCF in patients with T2DM and CP before and after non-surgical periodontal treatment and investigate the relationship. Participants with T2DM were included on the basis of assessment of their clinical characteristics, including: 1) diagnosis of T2DM of >1 year with no medication changes in the last 3 months; 2) no nonsteroidal or anti-inflammatory drugs within the previous 6 months; 3) no history of periodontal treatment 6 months before the study; and 4) having ‡16 teeth. CP was diagnosed as having mean AL ‡1 mm according to American Academy of Periodontology criteria. 16 Exclusion criteria were as follows: 1) aggressive periodontitis; 16 2) current or former use of tobacco in any form; or 3) any other systemic disease (hypertension, metabolic syndrome, cardiovascular disease, immune disease, malignant tumor, etc.) that can alter the course of periodontal disease.
MATERIALS AND METHODS

Participants
Participants were randomly divided into two groups: group 1, treatment; group 2, control. Eight of the 54 participants withdrew: in group 1, four participants dropped out because of personal reasons (such as sickness or no available time), and in group 2, four participants withdrew (one due to no available time, and three due to the occurrence of acute periodontitis in need of periodontal therapy). Twentythree patients made up group 1 (12 males and 11 females; mean age: 54.09 -6.57 years; mean body mass index [BMI]: 22.22 -0.64 kg/cm 2 ) and 23 in group 2 (10 males and 13 females; mean age: 55.52 -5.22 years; mean BMI: 22.14 -0.72 kg/cm 2 ). Participants in group 1 received oral hygiene instructions and non-surgical periodontal treatment, and those in group 2 received only oral hygiene instructions. During the experimental observation, all participants were required to maintain their current diet and medication.
Clinical Assessment and Periodontal Treatment
All participants were examined at the first clinic visit to assess periodontal condition. Each tooth was examined with a periodontal probe to measure probing depth (PD), clinical attachment level (CAL), bleeding on probing, and gingival index (GI). 17 Participants were reexamined after 3 and 6 months to reassess their periodontal conditions as described above.
All participants received oral hygiene instructions two or three times, including the use of interproximal cleaning aids by floss and interdental brushes. For participants in the treatment group, subgingival scaling and root planing were completed within 1 month of the first visit. Non-surgical periodontal treatment was not accompanied by any medications. All periodontal interventions were performed by a periodontist (YW).
GCF and Blood Collection GCF and blood samples were collected from all participants at baseline and after 3 and 6 months. GCF samples were collected in the morning, 2 to 3 hours after breakfast. The sites to be sampled were isolated with cotton rolls and gently air-dried. Paper strips § were gently placed for 30 seconds into the pocket until a minimum of resistance was felt. All samples containing blood and saliva were discarded. The collected samples were immediately transferred to microcentrifuge tubes and stored at -70°C. Blood (2 mL) was drawn before breakfast on the day of GCF sampling. After blood collection, serum and plasma were immediately separated for each blood sample and stored at -70°C. § Whatman Paper, Little Chalfont, UK.
Biochemical Assay GCF was extracted from paper strips by centrifugation. Serum and GCF visfatin concentrations were determined using an enzyme-linked immunosorbent assay kit i according to the manufacturer's instructions. Plasma glycated hemoglobin (HbA1c) level was measured by immunoturbidimetry.
Statistical Analyses
Descriptive data were normally distributed and are presented as mean -SD. Student t test and Pearson correlation were used to assess relationships among variables. P <0.05 was considered statistically significant. All data were analyzed using statistical software. ¶ Statistical analysis was accomplished by the Department of Epidemiology and Biostatistics of Fujian Medical University.
RESULTS
Demographic variables, age, sex, BMI, and number of teeth were not significantly different between groups, nor was T2DM duration (t test, P >0.05) ( Table 1) .
No periodontal measurements (GI, PD, or CAL) were significantly different between groups at baseline (t test, P >0.05). GI, PD, and CAL values of group 1 were significantly decreased 3 and 6 months after periodontal treatment compared to those of group 2 (t test, P <0.05) ( Table 2) .
Serum and GCF visfatin levels showed no significant difference between groups at baseline (t test, P >0.05). Three and 6 months after periodontal treatment, visfatin levels in GCF and serum decreased, and serum and GCF visfatin levels between groups showed statistically significant differences (t test, P <0.05). Plasma HbA1c was not significantly different at baseline and 3 months between groups (t test, P >0.05); however, HbA1c showed a significant difference at 6 months, with a slightly decreased level in group 1 (t test, P <0.01) (Table 3) . Moreover, according to the r values (Table 4) , visfatin in GCF and serum was positively correlated with HbA1c.
DISCUSSION
Previous studies have demonstrated that non-surgical periodontal treatment affects glycemic control in patients with T2DM. 18, 19 However, the mechanism of improvement is not yet well understood; it might be related to insulin resistance 20 or glucose and lipid metabolism through reduction of adipokines, such as visfatin. 21, 22 Visfatin is preferentially secreted by visceral adipose tissue 23 and can also be produced by neutrophils and macrophages. 21 Visfatin has been proven to induce tumor necrosis factor-a and IL-6 in human monocytes and to stimulate secretion of inflammatory mediators and proteases by various intracellular pathways. 24 It also has been shown to upregulate secretion of the pro-and anti-inflammatory cytokines IL-1b, IL-1Ra, and IL-10, and it upregulated nuclear factor-kB activity in a dose-dependent manner in human leukocytes. 25 Moreover, this adipokine can inhibit apoptosis of inflammatory cells 26, 27 and plays a key role in persistence of inflammation by inhibiting neutrophil apoptosis. Visfatin levels and expression of its messenger RNA (mRNA) are significantly increased in patients with T2DM, 28 inflammatory bowel disease, 25 and rheumatic arthritis. 29 Several studies have demonstrated that adipokines participate in various physiologic and pathologic processes, including immunity and inflammation. 30 In the present study, the results show that PD, GI, and CAL values decreased in group 1 after periodontal treatment in comparison with group 2. Slightly decreased PD and GI levels were found in group 2, which may be attributed to the effect of oral hygiene instruction on periodontal inflammation. The results suggest that non-surgical periodontal treatment could effectively improve periodontal inflammation, a result consistent with previous studies. Chen et al. 31 examined 134 patients with T2DM and CP and found that non-surgical periodontal treatment could efficiently improve periodontal and circulating inflammatory status.
The results of the present study show that periodontal treatment can significantly reduce visfatin in serum and GCF. Simultaneously, it was observed that visfatin correlated positively with plasma HbA1c and all periodontal parameters, suggesting that visfatin might play a role in the pathogenesis of periodontitis in patients with T2DM. Increased visfatin is a risk factor for periodontitis in patients who have T2DM, whereas decreased visfatin after periodontal treatment may reduce the risk for periodontitis. Thus, visfatin could be considered a potential marker.
Recently, attention has been paid to the source of visfatin. Ma et al. demonstrated that increased serum visfatin was derived from placenta in women with gestational diabetes. 32 A recent study of Friebe et al. showed that leukocytes were a major source of circulating visfatin, at least in adolescents. 33 However, whether GCF visfatin is the production of local periodontal tissue or transported from the circulation has not been clearly answered. A study predicted that visfatin was produced by periodontal ligament cells. 34 In the present work, the visfatin level was found to be greater in GCF than in serum in both groups, which suggests that visfatin might be secreted from periodontal tissue in response to inflammation. Thus, periodontal tissues could be a source of visfatin in GCF and the circulation system in patients with CP.
In this study, a significant decrease in visfatin was found in serum and GCF after 3 months of periodontal non-surgical treatment, accompanied by improved healthy conditions in patients. These cues suggested that periodontal non-surgical treatment is helpful in periodontitis therapy, and the therapeutic effect may be associated with visfatin. HbA1c (an index of glycometabolism) was decreased at 6 months after baseline, which was later than the decline of visfatin. Moreover, the concentration of visfatin was positively related to HbA1c. The authors hypothesize that the improvement of glycometabolism may result from the decline of visfatin. The molecular mechanism of visfatin in regulating HbA1c is still unclear, and further investigation is needed.
CONCLUSIONS
In this study, the authors evaluated the role of visfatin in patients with T2DM and CP before and after nonsurgical periodontal treatment. The data show that non-surgical periodontal treatment causes a reduction of visfatin and HbA1c levels in patients with periodontitis who have T2DM. Periodontal treatment was effective in glycometabolism control in patients with T2DM and periodontitis, and visfatin may be involved in the mechanism of glucose control. The findings of this study are helpful to provide evidence-based recommendations for clinicians. Prospective clinical studies with a larger scale and greater statistical power are required to better clarify the mechanisms of the possible effects of CP on T2DM.
